Alkermes – A global biopharmaceutical company

About Us

About Alkermes

Our Company Message From the CEO Locations

Leadership

Management Team Board of Directors

Collaborations

Strategic Partners

Products

Products Overview

United States

ARISTADA^® VIVITROL^® U.S. Products Using Alkermes Technologies Wholesaler and Purchasing Information

European Union

EU Products Using Alkermes Technologies

Research & Development

R&D Overview Our R&D Approach Pipeline Technology Platforms Manufacturing

Other Information

Clinical Trials Expanded Access

Responsibility

Alkermes Corporate Giving Investigator Initiated Trials Educational Grants Patient Engagement Support ALKERMES INSPIRATION GRANTS^®

Investors

Corporate Overview Press Releases Investor Events Stock Information SEC Filings Annual Reports

Financials

Snapshot Trading Statistics

Other Information

Email Alerts

News & Events

Press Releases Media Kit

Careers

Working Together Our Core Values Total Rewards Meet Our Employees Recruiting Agencies Equal Opportunity Employer

Job Opportunities

Jobs Overview Field Sales Roles All Available Roles

Latest News

Patients Switched to Alkermes’ ARISTADA® Showed Significant Improvement in Schizophrenia Symptoms After Inadequate Response or Intolerance to INVEGA SUSTENNA® Read More
Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders Read More
Alkermes to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Read More